Therapeutic approaches for prion disorders

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 4, 2007, Pages 613-630

  Ludewigs, Heike ^a   Zuber, Chantal ^a   Vana, Karen ^a   Nikles, Daphne ^a   Zerr, Inga ^b   Weiss, Stefan ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

37 67 kDa laminin receptor; Aderio associated virus; Amyloid; Bovine spongiform encephalopathy; Creutzfeldt Jakob disease; Laminin receptor; Lentivirus; LRP LR; Pentosan polysulfate; Prion; PrP; RNA interference; Therapy

Indexed keywords

4' IODOESORUBICIN; AMPHOTERICIN B; ANTHRACYCLINE; ANTIVIRUS AGENT; APTAMER; CHLORPROMAZINE; CONGO RED; DESIGNER DRUG; DEXTRAN SULFATE; DOXYCYCLINE; FLUPIRTINE; HEPARAN SULFATE; HM 5004; IMATINIB; LENTIVIRUS VECTOR; MEPACRINE; MONOCLONAL ANTIBODY; MS 8209; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PARVOVIRUS VECTOR; PENTOSAN POLYSULFATE; PHENOTHIAZINE DERIVATIVE; PLACEBO; POLYAMINE; POLYENE ANTIBIOTIC AGENT; PRION PROTEIN; SMALL INTERFERING RNA; STI 574; SURAMIN; TETRACYCLINE; TETRAPYRROLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTIVE IMMUNIZATION; ANTIVIRAL ACTIVITY; BLOOD BRAIN BARRIER; CLINICAL TRIAL; CREUTZFELDT JAKOB DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG TARGETING; ENCEPHALITIS; GENETIC HETEROGENEITY; HUMAN; NONHUMAN; PASSIVE IMMUNIZATION; PHENOTYPE; PRION DISEASE; REVIEW; RNA INTERFERENCE; VACCINATION; VIRAL GENE DELIVERY SYSTEM;

EID: 34547881525     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.4.613     Document Type: Review

References (158)

1. Vana K, Zuber C, Nikles D, Weiss S. Novel aspects of prions, their receptor molecules, and innovative approaches for TSE therapy. Cell. Mol. Neurobiol. 27(1), 107-128 (2007).
2. Ladogana A, Puopolo M, Croes EA et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology 64(9), 1586-1591 (2005).
3. Will RG, Ironside JW, Zeidler M et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347(9006), 921-925 (1996).
4. Will RG, Cousens SN, Farrington CP, Smith PG, Knight RS, Ironside JW. Deaths from variant Creutzfeldt-Jakob disease. Lancet 353(9157), 979 (1999).
5. Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302(5646), 871-874 (2003).
6. Mallucci GR, White MD, Farmer M et al. Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron 53(3), 325-335 (2007).
7. Farquhar CF, Dickinson AG. Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. J. Gen. Virol. 67(Pt 3), 463-473 (1986).
8. Gilch S, Winklhofer KF, Groschup MH et al. Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease. EMBO J. 20(15), 3957-3966 (2001).
9. Nunziante M, Kehler C, Maas E, Kassack MU, Groschup M, Schatzl HM. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication. J. Cell. Sci. 118(Pt 21), 4959-4973 (2005).
10. Gauczynski S, Nikles D, El-Gogo S et al. The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. J. Infect. Dis. 194(5), 702-709 (2006).
11. Adjou KT, Simoneau S, Sales N et al. A novel generation of heparan sulfate mimetics for the treatment of prion diseases. J. Gen. Virol. 84(Pt 9), 2595-2603 (2003).
12. Larramendy-Gozalo C, Barret A, Daudigeos E et al. Comparison of CR36, a new heparan mimetic, and pentosan polysulfate in the treatment of prion diseases. J. Gen. Virol. 88 (Pt 3), 1062-1067 (2007).
13. Caughey B, Raymond GJ. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J. Virol. 67(2), 643-650 (1993).
14. Farquhar C, Dickinson A, Bruce M. Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Lancet 353(9147), 117 (1999).
15. Whittle IR, Knight RS, Will RG. Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease. Acta Neurochir. (Wien) 148(6), 677-679 (2006).
16. Todd NV, Morrow J, Doh-ura K et al. Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. J. Infect. 50(5), 394-396 (2005).
17. Cordeiro Y, Machado F, Juliano L et al. DNA converts cellular prion protein into the β-sheet conformation and inhibits prion peptide aggregation. J. Biol. Chem. 276(52), 49400-49409 (2001).
18. Deleault NR, Geoghegan JC, Nishina K, Kascsak R, Williamson RA, Supattapone S. Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions. J. Biol. Chem. 280(29), 26873-26879 (2005).
19. Nandi PK, Leclerc E. Polymerization of murine recombinant prion protein in nucleic acid solution. Arch. Virol. 144(9), 1751-1763 (1999).
20. Kocisko DA, Vaillant A, Lee KS et al. Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. Antimicrob. Agents Chemother. 50(3), 1034-1044 (2006).
21. Cohen AS, Calkins E, Levene CI. Studies on experimental amyloidosis. I. Analysis of histology and staining reactions of casein-induced amyloidosis in the rabbit. Am. J. Pathol. 35, 971-989 (1959).
22. Glenner GG. Amyloid deposits and amyloidosis: the β-fibrilloses (second of two parts). N. Engl. J. Med. 302(24), 1333-1343 (1980).
23. Caughey B, Race RE. Potent inhibition of scrapie-associated Prp accumulation by congo red. J. Neurochem. 59(2), 768-771 (1992).
24. Caspi S, Halimi M, Yanai A, Sasson SB, Taraboulos A, Gabizon R. The anti-prion activity of Congo red. Putative mechanism. J. Biol. Chem. 273(6), 3484-3489 (1998).
25. Ingrosso L, Ladogana A, Pocchiari M. Congo red prolongs the incubation period in scrapie-infected hamsters. J. Virol. 69(1), 506-508 (1995).
26. Bos RP, Koopman JP, Theuws JLG, Henderson PT. The essential role of the intestinal flora in the toxification of orally-administered benzidine-dyes: internal exposure of rats to benzidine after intestinal azo reduction. Mutat. Res. 181, 327 (1987).
27. Rudyk H, Vasiljevic S, Hennion RM, Birkett CR, Hope J, Gilbert IH. Screening Congo red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells. J. Gen. Virol. 81(Pt 4), 1155-1164 (2000).
28. Poli G, Martino PA, Villa S et al. Evaluation of anti-prion activity of Congo red and its derivatives in experimentally infected hamsters. Arzneimittelforschung 54(7), 406-415 (2004).
29. Adjou KT, Demaimay R, Lasmezas C, Deslys JP, Seman M, Dormont D. MS-8209, a new amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapic. Antimicrob. Agents Chemother. 39(12), 2810-2812 (1995).
30. Pocchiari M, Schmittinger S, Masullo C. Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters. J. Gen. Virol. 68(Pt 1), 219-223 (1987).
31. Adjou KT, Demaimay R, Lasmezas CI, Seman M, Deslys JP, Dormont D. Differential effects of a new amphotericin B derivative, MS-8209, on mouse BSE and scrapie: implications for the mechanism of action of polyene antibiotics. Res. Virol. 147(4), 213-218 (1996).
32. Demaimay R, Adjou KT, Beringue V et al. Late treatment with polyene antibiotics can prolong the survival time of scrapie-infected animals. J. Virol. 71(12), 9685-9689 (1997).
33. Bolard J. Interaction of polyene antibiotics with membrane lipids: physicochemical studies of the molecular basis of selectivity. Drugs Exp. Clin. Res. 12(6-7), 613-618 (1986).
34. Beringue V, Lasmezas CI, Adjou KT et al. Inhibiting scrapie neuroinvasion by polyene antibiotic treatment of SCID mice. J. Gen. Virol. 80(Pt 7), 1873-1877 (1999).
35. Hartsel SC, Weiland TR, Amphotericin B binds to amyloid fibrils and delays their formation: a therapeutic mechanism? Biochemistry 42(20), 6228-6233 (2003).
36. Marella M, Lehmann S, Grassi J, Chabry J. Filipin prevents pathological prion protein accumulation by reducing endocytosis and inducing cellular PrP release. J. Biol. Chem. 277(28), 25457-25464 (2002).
37. Tagliavini F, Forloni G, Colombo L et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol. Biol. 300(5), 1309-1322 (2000).
38. Forloni G, Iussich S, Awan T et al. Tetracyclines affect prion infectivity. Proc. Natl Acad. Sci. USA 99(16), 10849-10854 (2002).
39. Caughey WS, Raymond LD, Horiuchi M, Caughey B. Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc. Natl Acad. Sci. USA 95(21), 12117-12122 (1998).
40. Priola SA, Raines A, Caughey WS. Porphyrin and phthalocyanine antiscrapie compounds. Science 287(5457), 1503-1506 (2000).
41. Priola SA, Raines A, Caughey W. Prophylactic and therapeutic effects of phthalocyanine tetrasulfonate in scrapie-infected mice. J. Infect. Dis. 188(5), 699-705 (2003).
42. Kocisko DA, Caughey WS, Race RE, Roper G, Caughey B, Morrey JD. A porphyrin increases survival time of mice after intracerebral prion infection. Antimicrob. Agents Chemother. 50(2), 759-761 (2006).
43. Supattapone S, Nguyen HO, Cohen FE, Prusiner SB, Scott MR. Elimination of prions by branched polyamines and implications for therapeutics. Proc. Natl Acad. Sci. USA 96(25), 14529-14534 (1999).
44. Winklhofer KF, Tatzelt J. Cationic lipopolyamines induce degradation of PrPSc in scrapie-infected mouse neuroblastoma cells. Biol. Chem. 381(5-6), 463-469 (2000).
45. Bera A, Nandi PK. Biological polyamines inhibit nucleic-acid-induced polymerisation of prion protein. Arch. Virol. 152(4), 655-668 (2007).
46. Deleault NR, Lucassen RW, Supattapone S. RNA molecules stimulate prion protein conversion. Nature 425(6959), 717-720 (2003).
47. Deleault NR, Harris BT, Rees JR, Supattapone S. Formation of native prions from minimal components in vitro. Proc. Natl Acad. Sci. USA 104(23), 9741-9746 (2007).
48. Merlini G, Ascari E, Amboldi N et al. Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin, with amyloid fibrils: inhibition of amyloidogenesis. Proc. Natl Acad. Sci. USA 92(7), 2959-2963 (1995).
49. Tagliavini F, McArthur RA, Canciani B et al. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science 276(5315), 1119-1122 (1997).
50. Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl Acad. Sci. USA 98(17), 9836-9841 (2001).
51. Ryou C, Legname G, Peretz D, Craig JC, Baldwin MA, Prusiner SB. Differential inhibition of prion propagation by enantiomers of quinacrine. Lab. Invest. 83(6), 837-843 (2003).
52. Doh-ura K, Ishikawa K, Murakami-Kubo I et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J. Virol. 78 (10), 4999-5006 (2004).
53. Barret A, Tagliavini F, Forloni G et al. Evaluation of quinacrine treatment for prion diseases. J. Virol. 77(15), 8462-9 (2003).
54. Soto C, Kascsak RJ, Saborio GP et al. Reversion of prion protein conformational changes by synthetic β-sheet breaker peptides. Lancet 355(9199), 192-197 (2000).
55. Weiss S, Proske D, Neumann M et al. RNA aptamers specifically interact with the prion protein PrR. J. Virol. 71(11), 8790-8797 (1997).
56. Sc formation. Chembiochem 3(8), 717-725 (2002).
57. Sc in prion-infected cells. J. Biol. Chem. 279(40), 41918-41927 (2004).
58. Korth C, Stierli B, Streit P et al. Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature 390(6655), 74-77 (1997).
59. Sc replication in infected cells. J. Biol. Chem. 280(12), 11247-11258 (2005).
60. Morel E, Andrieu T, Casagrande F et al. Bovine prion is endocytosed by human enterocytes via the 37 kDa/67 kDa laminin receptor. Am. J. Pathol. 167(4), 1033-1042 (2005).
61. Paramithiotis E, Pinard M, Lawton T et al. A prion protein epitope selective for the pathologically misfolded conformation. Nat. Med. 9(7),893-899 (2003).
62. Enari M, Flechsig E, Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. Natl Acad. Sci. USA 98(16), 9295-9299 (2001).
63. Peretz D, Williamson RA, Kaneko K et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412(6848), 739-743 (2001).
64. Flechsig E, Shmerling D, Hegyi I et al. Prion protein devoid of the octapeptide repeat region restores susceptibility to scrapie in PrP knockout mice. Neuron 27(2), 399-408 (2000).
65. c by anti-PrP antibody prevents protease-resistant PrP formation. J. Gen. Virol. 85 (Pt 11), 3473-3482 (2004).
66. c degradation. J. Neurochem. 89(2), 454-463 (2004).
67. Sc propagation in prion-infected cells. J. Biol. Chem. 278(20), 18524-18531 (2003).
68. Sc. Proc. Natl Acad Sci. USA 101(28), 10404-10409 (2004).
69. Heppner FL, Musahl C, Arrighi I et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294(5540), 178-182 (2001).
70. White AR, Enever P, Tayebi M et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422(6927), 80-83 (2003).
71. Sigurdsson EM, Sy MS, Li R et al. Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci. Lett. 336(3), 185-187 (2003).
72. Hundt C, Peyrin JM, Haik S et al. Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor. EMBO J. 20(21), 5876-5886 (2001).
73. Gauczynski S, Peyrin JM, Haik S et al. The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J. 20(21), 5863-5875 (2001).
74. Leucht C, Simoneau S, Rey C et al. The 37 kDa/67 kDa laminin receptor is required for PrP(Sc) propagation in scrapie-infected neuronal cells. EMBO Rep. 4(3), 290-295 (2003).
75. Zuber C, Knackmuss S, Rey C et al. Single chain Fv antibodies directed against the 37kDa/67kDa laminin receptor as therapeutic tools in prion diseases. Mol. Immunol. (2007) (Epub ahead of print).
76. Pankiewicz J, Prelli F, Sy MS et al. Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur. J. Neurosci. 23(10), 2635-2647 (2006).
77. Solforosi L, Criado JR, McGavern DB et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 303(5663), 1514-1516 (2004).
78. Adamson CS, Yao Y, Visiljevic S, Sy MS, Ren J, Jones IM. Novel single chain antibodies to the prion protein identified by phage display. Virology 358(1), 166-177 (2007).
79. Leclerc E, Liemann S, Wildegger G, Vetter SW, Nilsson F. Selection and characterization of single chain Fv fragments against murine recombinant prion protein from a synthetic human antibody phage display library. Hum. Antibodies 9(4), 207-214 (2000).
80. Donofrio G, Heppner FL, Polymenidou M, Musahl C, Aguzzi A. Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies. J. Virol. 79(13), 8330-8338 (2005).
81. Vetrugno V, Cardinale A, Filesi I et al. KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity. Biochem. Biophys. Res. Commun. 338(4), 1791-1797 (2005).
82. Buchholz CJ, Bach P, Nikles D, Kalinke U. Prion protein-specific antibodies for therapeutic intervention of transmissible spongiform encephalopathies. Expert Opin. Biol. Ther. 6(3), 293-300 (2006).
83. Polymenidou M, Heppner FL, Pellicioli EC et al. Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc. Natl Acad. Sci. USA 101(Suppl. 2), 14670-14676 (2004).
84. Nikles D, Bach P, Boller K et al. Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP J. Virol. 79(7), 4033-4042 (2005).
85. Goni F, Knudsen E, Schreiber F et al. Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 133(2), 413-421 (2005).
86. Fernandez-Borges N, Brun A, Whitton JL et al. DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge. J. Virol. 80(20), 9970-9976 (2006).
87. Handisurya A, Gilch S, Winter D et al. Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells. FEBS J. 274(7), 1747-1758 (2007).
88. Sc vaccine using a mouse model system. Presented at: Prion 2006 Conference (Strategies, Advances and Trends Towards Protection of Society). Torino, Italy, 3-6 October 2006.
89. Mathiason CK, Powers JG, Dahmes SJ et al. Infectious prions in the saliva and blood of deer with chronic wasting disease. Science 314(5796), 133-136 (2006).
90. Priola SA, Caughey B. Inhibition of scrapie-associated PrP accumulation. Probing the role of glycosaminoglycans in amyloidogenesis. Mol. Neurobiol. 8(2-3), 113-120 (1994).
91. Kaneko K, Zulianello L, Scott M et al. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc. Natl Acad. Sci. USA 94(19), 10069-10074 (1997).
92. Hölscher C, Delius H, Bürkle A. Overexpression of nonconvertible PrPc δ114-121 in scrapie-infected mouse neuroblastoma cells leads to trans-dominant inhibition of wild-type PrP(Sc) accumulation. J. Virol. 72(2), 1153-1159 (1998).
93. Perrier V, Kaneko K, Safar J et al. Dominant-negative inhibition of prion replication in transgenic mice. Proc. Natl Acad. Sci. USA 99(20), 13079-13084 (2002).
94. Furuya K, Kawahara N, Yamakawa Y et al. Intracerebroventricular delivery of dominant negative prion protein in a mouse model of iatrogenic Creutzfeldt-Jakob disease after dura graft transplantation. Neurosci. Lett. 402(3), 222-226 (2006).
95. Sc formation by lentiviral gene transfer of PrP containing dominant negative mutations. J. Cell. Sci. 117(Pt 23), 5591-5597 (2004).
96. Bueler H, Aguzzi A, Sailer A et al. Mice devoid of PrP are resistant to scrapie. Cell 73(7), 1339-1347 (1993).
97. Vana K, Weiss S. A trans-dominant negative 37kDa/67kDa laminin receptor mutant impairs PrP(Sc) propagation in scrapie-infected neuronal cells. J Mol. Biol. 358(1), 57-66 (2006).
98. Daude N, Marella M, Chabry J. Specific inhibition of pathological prion protein accumulation by small interfering RNAs. J. Cell. Sci. 116(Pt 13), 2775-2779 (2003).
99. Golding MC, Long CR, Carmell MA, Hannon GJ, Westhusin ME. Suppression of prion protein in livestock by RNA interference. Proc. Natl Acad. Sci. USA 103(14), 5285-5290 (2006).
100. Pfeifer A, Eigenbrod S, Al-Khadra S et al. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J. Clin. Invest. 116(12), 3204-3210 (2006).
101. Bueler H, Fischer M, Lang Y et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356(6370), 577-582 (1992).
102. Richt JA, Kasinathan P, Hamir AN et al. Production of cattle lacking prion protein. Nat. Biotechnol. 25(1), 132-8 (2007).
103. Leucht C, Vana K, Renner-Muller I et al. Knock-down of the 37-kDa/ 67-kDa laminin receptor in mouse brain by transgenic expression of specific antisense LRP RNA. Transgenic Res. 13(1), 81-85 (2004).
104. Rieger R, Edenhofer F, Lasmezas CI, Weiss S. The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nat. Med. 3(12), 1383-1388 (1997).
105. Zuber C, Ludewigs H, Weiss S. Therapeutic approaches targeting the prion receptor LRP/LR. Vet. Microbiol. 123, 387-393 (2007).
106. Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain 129, 2241-2265 (2006).
107. Gresser I, Maury C, Chandler RL. Failure to modify scrapie in mice by administration of interferon or anti-interferon globulin. J. Gen. Virol. 64, 1387-1389 (1983).
108. Grigoriev V, Adjou KT, Sales N et al. Effects of the polyene antibiotic derivative MS-8209 on the astrocyte lysosomal system of scrapie-infected hamsters. J. Mol. Neurosci. 18, 271-281 (2002).
109. Terzano MG, Montanari E, Calzetti S, Mancia D, Lechi A. The effect of amantadine on arousal and EEG patterns in Creutzfeldt-Jakob disease. Arch. Neurol. 40(9), 555-559 (1983).
110. Dealler S, Rainov N. Pentosan polysulfate as a prophylactic and therapeutic agent against prion disease. I. Drugs 6, 470-478 (2003).
111. Parry A, Baker I, Stacey R, Wimalaratna S. Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate. J. Neurol. Neurosurg. Psychiatry 78(7), 733-734 (2007).
112. Farquard C. Sodium pentosan polysulfate use in rodent models of Scrapie and BSE. Oral presentation at: Prion 2006 Conference (Strategies, Advances and Trends Towards Protection of Society). Torino, Italy, 3-6 October 2006.
113. Otto M, Cepek L, Ratzka P et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology 62, 714-718 (2004).
114. Haik S, Brandel JP, Salomon D et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology 63(12), 2413-2415 (2004).
115. Forloni G, Colombo L, Girola L, Tagliavini F, Salamona M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett. 487(3), 404-407 (2001).
116. Tagliavini F. Prion disease therapeutics: Tetracyclic compounds in in vitro models, animal models and patients with Creutzfeldt-Jakob Disease. Oral presentation at: 6th National TSE-Forschungsplattform Congress. Greifswald, Germany, 26-28 June 2007.
117. Parchi P, Giese A, Capellari S et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann. Neurol. 46, 224-233 (1999).
118. Heinemann U, Krasnianski A, Meissner B et al. Creutzfeldt-Jakob disease in Germany: a prospective 12-years surveillance. Brain 130, 1350-1359 (2007).
119. Zerr I, Schulz-Schaeffer WJ, Giese A et al. Current clinical diagnosis in CJD: identification of uncommon variants. Ann. Neurol. 48, 323-329 (2000).
120. Sanchez-Juan P, Green A, Ladogana A et al. Cerebrospinal fluid tests in the differential diagnosis of CJD. Neurology 67(4), 637-643 (2006).
121. Tschampa HJ, Kallenberg K, Urbach H et al. MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement. Brain 128(Pt 9), 2026-2033 (2005).
122. Pocchiari M, Poupolo M, Croes EA et al. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain 10, 2348-2359 (2004).
123. Cordery RJ, Hall M, Cipolotti L et al. Early cognitive decline in Creutzfeldt-Jakob disease associated with human growth hormone treatment. J. Neurol. Neurosurg. Psychiatry 74, 1412-1416 (2003).
124. Cordery RJ, Alner K, Cipolotti L et al. The neuropsychology of variant CJD: a comparative study with inherited and sporadic forms of prion disease. J. Neurol. Neurosurg. Psychiatry 76, 330-336 (2005).
125. Hamaguchi T, Kitamoto T, Sato T et al. Clinical diagnosis of MM2-type sporadic Creutzfeldt-Jakob disease. Neurology 64, 643-8 (2005).
126. Zerr I, Poser S. Clinical diagnosis and differential diagnosis of CJD and vCJD. With special emphasis on laboratory tests. APMIS 110, 88-98 (2002).
127. Brown P, Gibbs CJ Jr, Rodgers-Johnson P et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann. Neurol. 35(5), 513-529 (1994).
128. Otto A, Zerr I, Lantsch M, Weidehaas K, Riedemann C, Poser S. Akinetic mutism as a classification criterion for the diagnosis of Creutzfeldt-Jakob disease. J. Neurol. Neurosurg. Psychiatry 64(4), 524-528 (1998).
129. Krasnianski A, Meissner B, Schulz-Schaeffer W et al. Clinical features and diagnosis of the MM2 cortical subtype of sporadic Creutzfeldt-Jakob disease. Arch. Neurol. 63(6), 876-880 (2006).
130. Krasnianski A, Schulz-Schaeffer WJ, Kallenberg K et al. Clinical findings and diagnostic tests in the MV-2 subtype of sporadic CJD. Brain 129, 2288-2296 (2006).
131. Meissner B, Westner I, Kallenberg K et al. Sporadic Creutzfeldt-Jakob disease: clinical and diagnostic characteristics of the rare VV1 type. Neurology 65(10), 1544-1550 (2005).
132. de Silva R. Human spongiform encephalopathy. In: Prion Diseases. Baker HF, Ridley RM (Eds). Humana Press, NJ, USA 15-33 (1996).
133. Haïk S, Brandel JP, Sazdovitch V et al. Dementia with Lewy bodies in a neuropathologic series of suspected Creutzfeldt-Jakob disease. Neurology 55, 1401-1404 (2000).
134. Poser S, Mollenhauer B, Krauss A et al. How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain 122, 2345-2351 (1999).
135. Tschampa HJ, Neumann M, Zerr I et al. Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease. J. Neurol. Neurosurg. Psychiatry 71, 33-39 (2001).
136. Van Everbroeck B, Dobbeleir I, De Waele M, De Deyn P, Martin J-J, Cras P. Differential diagnosis of 201 possible Creutzfeldt-Jakob disease patients. J. Neurol. 251, 298-304 (2004).
137. Boesenberg C, Schulz-Schaeffer WJ, Meissner B et al. Clinical course in young patients with sporadic Creutzfeldt-Jakob disease. Ann. Neurol. 58, 533-543 (2005).
138. Ladogana A, Puopolo M, Croes EA et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology 64, 1586-1591 (2005).
139. Braaten AJ, Parsons TD, McCue R, Sellers A, Burns WJ. Neurocognitive differential diagnosis of dementing diseases: Alzheimer's dementia, vascular dementia, frontotemporal dementia, and major depressive disorder. Int. J. Neurosci. 11 6(11), 1271-1293 (2006).
140. Doh-ura K. Pentosan polysulfate and amyloidophilic chemicals for prion diseases. Presented at: Prion 2006 Conference (Strategies, Advances and Trends Towards Protection of Society). Torino, Italy, 3-6 October 2006.
141. Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wuthrich K. NMR structure of the mouse prion protein domain PrP(121-321). Nature 382(6587), 180-182 (1996).
142. Supattapone S, Wille H, Uyechi L et al. Branched polyamines cure prion-infected neuroblastoma cells. J. Virol. 75(7), 3453-3461 (2001).
143. Sc binding antibodies are potent inhibitors of prion replication in cell lines. J. Biol. Chem. 279(38), 39671-39676 (2004).
144. David AS, Grant R, Ballantyne JP. Unsuccessful treatment of Creutzfeldt-Jakob disease with acyclovir [letter]. Lancet 1(8375), 512-513 (1984).
145. Newman PK. Acyclovir in Creutzfeldt-Jakob disease [letter]. Lancet 1(8380), 793 (1984).
146. Braham J. Amantadine in the treatment of Creutzfeldt-Jakob disease [letter]. Arch. Neurol. 41(6), 585-586 (1984).
147. Ratcliffe J, Rittman A, Wolf S, Verity MA. Creutzfeldt-Jakob disease with focal onset unsuccessfully treated with amantadine. Bull. Los Angeles Neurol. Soc. 40(1), 18-20 (1975).
148. Terzano MG, Mancia D, Manzoni GC. Periodic activities in Creutzfeldt-Jakob disease and epilepsy. Prog. Clin. Biol. Res. 124(199), 199-226 (1983).
149. Braham J. Jakob-Creutzfeldt disease: treatment by amantadine. Br. Med. J. 4, 212-213 (1971).
150. Sanders WL. Creutzfeldt-Jakob disease treated with amantadine. J. Neurol. Neurosurg. Psychiatry 42(10), 960-961 (1979).
151. Sanders WL, Dunn TL. Creutzfeldt-Jakob disease treated with amantidine. A report of two cases. J. Neurol. Neurosurg. Psychiatry 36(4), 581-584 (1973).
152. Masullo C, Macchi G, Xi YG, Pocchiari M. Failure to ameliorate Creutzfeldt-Jakob disease with amphotericin B therapy [letter]. J. Infect. Dis. 165(4), 784-785 (1992).
153. Kovanen J, Haltia M, Cantell K. Failure of interferon to modify Creutzfeldt-Jakob disease. Br. Med. J. 280, 902 (1980).
154. Nakajima M, Yamada T, Kusuhara T et al. Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement. Geriatr. Cogn. Disord. 17, 158-163 (2004).
155. Benito-Leon J. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology 64(10), 1824 (2005).
156. Satoh K, Shirabe S, Eguchi K et al. Toxicity of quinacrine can be reduced by co-administration of P-glycoprotein inhibitor in sporadic Creurzfeldt-Jakob disease. Cell. Mol. Neurobiol. 24(6), 873-875 (2004).
157. Scoaazec JY, Krolak-Salmon P, Casez O et al. Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease. Ann. Neurol. 53(4), 546-547 (2003).
158. Furlow TJ, Whitley RJ, Wilmes FJ. Repeated suppression of Creutzfeldt-Jakob disease with vidarabine [letter]. Lancet 2(8297), 564-565 (1982).